-
Mar 19, 2021Received FDA IDE Approval for Pivotal Study of C-Scan®
Mar 15, 2021Company expects to commence U.S. pivotal trial in late 2021- Aug 6, 2020IDE submission to the FDA for C-Scan® planned for the end of 2020; Initiation of a U.S. pivotal study planned for 2021
- May 27, 2020Strengthened balance sheet through a total of $16.3 million in registered direct offerings and a private placement of ordinary shares in the first half of 2020
